Announcement • Dec 11
Jamie Forrest acquired an additional minority stake in Branded Legacy Inc (OTCPK:BLEG). Jamie Forrest acquired an additional minority stake in Branded Legacy Inc (OTCPK:BLEG) on December 10, 2025. On completion, effective immediately all legacy subsidiaries have been fully divested and are no longer affiliated with Branded Legacy, Inc. in any capacity. All previous officers and directors have been removed and have no continuing role, affiliation, compensation, influence, or future involvement with the Company. No shares, compensation, convertible notes, or any other consideration will be issued to prior management or related parties for past services, as they did not deliver on their business plan and left the Company in a compromised state.
Jamie Forrest completed the acquisition of an additional minority stake in Branded Legacy Inc (OTCPK:BLEG) on December 10, 2025. Announcement • Aug 12
Branded Legacy Inc. Appoints Kristian Thorlund as Chairman Branded Legacy Inc. announced that following the close of acquisition of Bio Legacy Evaluative Group, Dr. Kristian Thorlund will assume the role of Chairman of Branded Legacy Inc. Announcement • Jul 29
Branded Legacy Inc Appoints Amin Janmohamed as CEO Branded Legacy Inc. announced the execution of a non-binding Letter of Intent (LOI) to acquire Bio-Legacy Evaluative Group. The LOI, fully executed by both parties, outlines the proposed acquisition of 100% of Bio-Legacy Evaluative Group's equity interests, assets, intellectual property, and operations in exchange for $1.5 million worth of Branded Legacy's Preferred D stock. This strategic move aligns with Branded Legacy's commitment to expanding its portfolio into high-growth sectors addressing global health crises, such as addictions and vaccine accessibility. Bio-Legacy Evaluative Group, led by President & CEO Amin Janmohamed, has assembled a world-class team of experts including Prof. Eran Bendavid, MD (Research Lead, Stanford Professor), Prof. Sonal Singh, MD (Medical Lead, UMass Professor), Prof. Martin Schechter, MD, PhD (Scientific Advisor), and others renowned in addiction medicine, biostatistics, and business development. Upon completion, Bio-Legacy Evaluative Group will become a wholly-owned subsidiary of Branded Legacy, integrating its innovative pipeline—including manufacturing prototyping targeted for Third Quarter 2025, clinical trials in 2026, and market readiness for the naloxone device by First Quarter 2027—to drive revenue growth. Projected revenues for Bio-Legacy Evaluative Group under average growth scenarios could reach up to $183.3 million by Year 5. Following the closing of the acquisition, Amin Janmohamed will assume the roles of CEO and Chairman of Branded Legacy Inc., leveraging his experience as a pharmacist, clinical studies investigator, and executive to guide the combined entity's strategic direction. 
